Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The incidence of colorectal cancer (CRC) in individuals younger than 50 years of age (early-onset CRC) is increasing. Early-onset CRC often present at advanced stage, suggesting a more aggressive cancer course compared to late-onset CRC (age 50-79). This nationwide cohort study estimates the incidence of recurrence following early-onset CRC and late-onset CRC.
Methods: The study included all Danish patients <80 years old operated for first-time Union for International Cancer Control (UICC) stage I-III CRC between January 2004 and December 2019. Recurrence status was determined by applying a validated algorithm to individual-level data from nationwide health registries. The 5-year cumulative incidence functions (CIF) of recurrence were reported for early-onset versus late-onset CRC. The difference in time to recurrence was estimated as a time ratio (TR) using an accelerated failure time model.
Findings: Among 25,729 CRC patients, 1441 (5.6%) had early-onset CRC. Compared to late-onset CRC, early-onset was associated with advanced disease stages and higher treatment intensity. The 5-year CIF of recurrence was 29% (95% CI: 26%-31%) in early-onset versus 21% (95% CI: 21%-22%) in late-onset CRC. The higher CIF of recurrence for early-onset patients persisted in stage-stratified analysis. Time to recurrence was shorter in early-onset versus late-onset patients with TR = 0.76 (95% CI: 0.67-0.85). The 5-year CIF of recurrence decreased from 2004 to 2019 for both early- and late-onset patients-most prominent for early-onset patients.
Interpretation: Early-onset CRC was associated with higher incidence of recurrence at all disease stages. Indicating that the increased risk is not explained by delayed diagnosis. The excess risk diminished from 2004 to 2019, suggesting that early-onset CRC may achieve a similar recurrence risk as late-onset CRC in a contemporary setting.
Funding: Aarhus University, Novo Nordisk Foundation, Innovation Fund Denmark, and the Danish Cancer Society.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483332 | PMC |
| http://dx.doi.org/10.1016/j.lanepe.2024.101093 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidemiology of Early-onset Colorectal Cancer in a Safety-net Hospital System in Texas.
J Clin Gastroenterol
October 2025
Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine.
Goals: We aimed to characterize risk factors for early versus advanced-stage early-onset colorectal cancer (eoCRC) at our safety-net hospital system.
Background: Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in the United States. Rates of CRC diagnosis in young adults (age below 50) have been rising despite an overall decrease in CRC.
Risk of colorectal cancer by family history of both colorectal carcinomas and colorectal polyps: a nationwide cohort study.
Cancer Commun (Lond)
September 2025
Risk Adapted Prevention Group, Division of Primary Cancer Prevention, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Background: The increased risk of colorectal cancer (CRC) associated with family history of both colorectal in situ or invasive carcinomas (Stage 0 to IV) and colorectal polyps is attributed solely to family history of CRC, resulting in an underestimation of the actual risk. We aimed to assess the association between overall and early-onset CRC (EOCRC) risk and family history of both colorectal carcinomas and polyps.
Methods: We conducted a nationwide cohort study leveraging Swedish family-cancer datasets with follow-up from 1964 to 2018.
Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients.
ESMO Open
September 2025
Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy.
Background: Early-onset colorectal cancer (EO-CRC, ≤50 years of age) exhibits unique clinical and biological characteristics when compared with average-onset CRC (AO-CRC), but its overall molecular profile is still not well studied.
Materials And Methods: We retrospectively analysed 1209 patients with metastatic CRC profiled using FoundationOne® CDx, a clinically validated next-generation sequencing assay targeting 324 cancer-related genes. Patients were classified as EO-CRC (n = 298) or AO-CRC (n = 911).
Precision Oncology Through Dialogue: AI-HOPE-RTK-RAS Integrates Clinical and Genomic Insights into RTK-RAS Alterations in Colorectal Cancer.
Biomedicines
July 2025
Department of Integrative Translational Sciences, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
The RTK-RAS signaling cascade is a central axis in colorectal cancer (CRC) pathogenesis, governing cellular proliferation, survival, and therapeutic resistance. Somatic alterations in key pathway genes-including KRAS, NRAS, BRAF, and EGFR-are pivotal to clinical decision-making in precision oncology. However, the integration of these genomic events with clinical and demographic data remains hindered by fragmented resources and a lack of accessible analytical frameworks.
View Article and Find Full Text PDFA Pattern of Increased Aggressiveness for Colorectal Cancer in Northern Mexico: A Multicenter Retrospective Cohort From 2018 to 2023.
Arch Med Res
August 2025
Department of Rheumatology, Hospital Angeles Chihuahua, Chihuahua, Mexico.
Background: Colorectal cancer (CRC) is the third most prevalent cancer worldwide and the second leading cause of cancer-related deaths. Early-onset CRC is often more aggressive and is on the rise. In Mexico, 16,082 cases were diagnosed in 2022; however, epidemiological data remain limited-especially in northern regions where red meat consumption is high and screening adherence is low.
View Article and Find Full Text PDF